Company: APM
Filing Date: 2025-07-15
Form Type: DRS
Source: 0001213900-25-063899
Chunk: 45

Company: Aptorum Group Ltd
Filing Date: 2025-07-15
Form: DRS
Chunk 45
---
 forum selection provision will not apply to claims arising
under the Exchange Act or any other claim for which the federal courts have exclusive jurisdiction.

<div align='center'>19</div>

The Proposed Charter will also provide that, unless
Combined Company consents in writing to the selection of an alternative forum, to the fullest extent permitted by law, the federal district
courts of the United States shall be the exclusive forum for the resolution of any complaint asserting a cause of action arising under
the Securities Act. The Proposed Charter will further provide that any person or entity purchasing or otherwise acquiring any interest
in shares of Combined Company Common Stock is deemed to have notice of and consented to the provisions of the Proposed Charter described
above.

The forum selection provisions in the Proposed
Charter may have the effect of discouraging lawsuits against the Combined Company’s directors and officers. The enforceability of
similar choice of forum provisions in other companies’ certificates of incorporation has been challenged in legal proceedings and
there is uncertainty as to whether a court would enforce such provisions. In addition, investors cannot waive compliance with the federal
securities laws and the rules and regulations thereunder. If the enforceability of the Combined Company’s forum selection provisions
were to be challenged, it may incur additional costs associated with resolving such challenge. While the Combined Company currently has
no basis to expect any such challenge would be successful, if a court were to find its forum selection provisions to be inapplicable or
unenforceable with respect to one or more of these specified types of actions or proceedings, the Combined Company may incur additional
costs associated with having to litigate in other jurisdictions, which could result in a diversion of the time and resources of the Combined
Company’s employees, management and board of directors, and could have an adverse effect on its business, financial condition and
results of operations.

RISKS RELATED TO COMPANY

Risks Related to the Preclinical and Clinical Development of Our Drug Candidates

We currently do not generate revenue from product sales and may never become profitable; unless we can raise more capital through additional financings, of which there can be no guarantee.

Our ability to generate revenue
and become profitable depends upon our ability to successfully complete the development of, and obtain the necessary regulatory approvals
for, the drug candidates in our Lead Projects and any future drug candidates we may develop, as we do not currently have any drugs that
are available for commercial sale. We expect to continue to incur losses before commercialization of our drug candidates and any future